246 related articles for article (PubMed ID: 10085745)
1. [Transmitter dysfunction in patients with schizophrenia. Significance for cognitive functioning and treatment].
Glenthøj BY; Mackeprang T; Bille AE; Hemmingsen RP
Ugeskr Laeger; 1999 Mar; 161(10):1391-8. PubMed ID: 10085745
[TBL] [Abstract][Full Text] [Related]
2. The neurobiology of cognition in schizophrenia.
Tamminga CA
J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
[TBL] [Abstract][Full Text] [Related]
3. The neurobiology of cognition in schizophrenia.
Tamminga CA
J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
[TBL] [Abstract][Full Text] [Related]
4. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.
Jann MW
Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443
[TBL] [Abstract][Full Text] [Related]
5. Treatment of cognitive dysfunction in schizophrenia.
Peuskens J; Demily C; Thibaut F
Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
[TBL] [Abstract][Full Text] [Related]
6. The neurochemical circuitry of schizophrenia.
Carlsson A
Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S10-4. PubMed ID: 16508890
[TBL] [Abstract][Full Text] [Related]
7. [Current status of biochemical hypotheses in the pathogenesis of schizophrenia].
Kornhuber J; Weller M
Nervenarzt; 1994 Nov; 65(11):741-54. PubMed ID: 7816150
[TBL] [Abstract][Full Text] [Related]
8. [Cognitive dysfunction and electroencephalogram in schizophrenia].
Matsuoka H; Nakamura M
Seishin Shinkeigaku Zasshi; 2005; 107(4):307-22. PubMed ID: 15920943
[TBL] [Abstract][Full Text] [Related]
9. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
Wiesel FA
Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610
[TBL] [Abstract][Full Text] [Related]
10. [Psychopharmacologic approaches to schizophrenic psychoses].
Giacardy-Paty M; Soubrouillard C; Blin O
Encephale; 1995 Jun; 21 Spec No 3():3-8. PubMed ID: 7628339
[TBL] [Abstract][Full Text] [Related]
11. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
Maćkowiak M; Czyrak A; Wedzony K
Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
[TBL] [Abstract][Full Text] [Related]
12. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
Marek GJ
Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
[TBL] [Abstract][Full Text] [Related]
13. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?
Meltzer HY; Sumiyoshi T
Behav Brain Res; 2008 Dec; 195(1):98-102. PubMed ID: 18707769
[TBL] [Abstract][Full Text] [Related]
14. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
Millan MJ; Brocco M
Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
[TBL] [Abstract][Full Text] [Related]
15. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
16. Neural basis of psychosis-related behaviour in the infection model of schizophrenia.
Meyer U; Feldon J
Behav Brain Res; 2009 Dec; 204(2):322-34. PubMed ID: 19154759
[TBL] [Abstract][Full Text] [Related]
17. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function.
Swerdlow NR; Light GA; Cadenhead KS; Sprock J; Hsieh MH; Braff DL
Arch Gen Psychiatry; 2006 Dec; 63(12):1325-35. PubMed ID: 17146007
[TBL] [Abstract][Full Text] [Related]
18. On the trail of a cognitive enhancer for the treatment of schizophrenia.
Stip E; Chouinard S; Boulay LJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
[TBL] [Abstract][Full Text] [Related]
19. Conventional versus novel antipsychotics: changing concepts and clinical implications.
Remington G; Chong SA
J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
[TBL] [Abstract][Full Text] [Related]
20. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
